The global biologics market is anticipated to reach USD 399.5 billion by
2025, according to a new report by Grand View Research, Inc. Introduction of
targeted therapies coupled with rising adoption of patient centric personalized
medicine anticipated to fuel demand. Ever-increasing understanding of the cell
physiology and stress, as well as the factors involved in protein production
and heterologous gene expression have empowered the use of different living
factories.
These living factories are the prokaryotic and eukaryotic cells.
Enhancement of drug functionality through achieving successful protein folding
and post-translational modifications is supportive for projected progress rate.
 |
U.S. Biologics market share, by disease category, 2014 - 2025
(USD Billion)
|
Moreover, rising adoption of biopharmaceuticals over chemically synthesized
molecules is expected to propel revenue generation significantly. In addition
to this, presence of several metabolic disorders that can be treated through
the use of biologics is attributive to influence demand.
Combination of advanced bioengineering technologies for biopharmaceutical
production is expected to boost progress in pharmaceutical industry. With
recent advances in automation, the selection process can be done through high
throughput screening (HTS) system for selection of viable clones.
 |
Biologics market, by region, 2015 (USD Billion)
|
Aforementioned method enables robust production of biopharmaceutical
products by obtaining high-producing cell line. Advances with respect to
upstream and downstream processing would directly translate into the growth in
revenue for this market at a larger level.
However, development of biosimilars is expected to restrain the biologics
year on year growth to certain extent. Although, the regulatory approval
pathway for these products is not framed yet some drug manufacturers are opting
to invest in the development of biobetters.
In depth research report on Biologics Market
Further key findings from the report suggest:
·
Microbial
expression systems dominated the market with respect to biopharmaceutical
manufacturing
·
Presence of
substantial number of products manufactured through the use of microbial
sources can be attributed for largest share
·
Higher usage
of monoclonal antibodies for the treatment of different diseases responsible
for revenue generation
·
Moreover,
pipeline drugs in the phase of development anticipated to bolster growth
·
Significant
development pertaining to vaccines and increasing adoption anticipated to fuel
progress
·
Oncology
dominated over a decade and is expected to sustain its share over the forecast
period.
·
Introduction
of novel biologics with high efficacy coupled with the augmenting incidences of
cancer is the vital impact rendering factor.
·
Substantial
sales of biologics in the U.S. can be attributed for the largest share of North
American market.
·
Established
participants are implementing the manufacture of complex moieties in-house,
which pronounces for the larger share of in-house manufacturing.
·
Asia Pacific
is projected to showcase fastest growth in the coming years.
·
Increasing
penetration of the biologics in the developing economies is expected to
contribute in the projected growth.
·
Moreover, the
university based projects implemented herein are attributive for the projected
growth.
·
Key players
contributing in this market are F Hoffman La Roche, Samsung Biologics,
Celltrion, Pfizer Inc., Amgen, Novo Nordisk A/S, Sanofi, Abbvie Inc., Merck
& Co. Inc, Addgene, Johnson & Johnson Services Inc., and Eli Lilly
& Company.
·
These
participants are investing in the hybrid business models through providing
technology and service platforms.
·
Such
milestones and royalties from partnered programs enables the cash flow
generation which can be utilized in proprietary R&D.
Grand View Research has segmented the biologics market on the basis of
source, product, manufacturing, disease category, and region:
Biologics Source Outlook (Revenue, USD
Billion, 2014 - 2025)
·
Microbial
·
Mammalian
·
Others
Biologics Product Outlook (Revenue, USD
Billion, 2014 - 2025)
·
Monoclonal
Antibodies
o
By application
§
Diagnostic
§
Biochemical
Analysis
§
Diagnostic
Imaging
§
Therapeutic
§
Direct MAB
Agents
§
Targeting MAB
Agents
§
Protein Purification
§
Others
o
By type
§
Murine
§
Chimeric
§
Humanized
§
Human
§
Others
o
Vaccines
o
Recombinant
Proteins
o
Antisense,
RNAi, & Molecular Therapy
o
Others
Biologics Manufacturing Outlook (Revenue, USD
Billion, 2014 - 2025)
·
In-house
·
Outsourced
Biologics Disease Category Outlook (Revenue,
USD Billion, 2014 - 2025)
·
Oncology
o
By Product
§
MABs
§
Vaccines
§
Recombinant
Proteins
§
Antisense,
RNAi, & Molecular Therapy
§
Others
(Certain products under trials related to blood products etc)
·
Infectious
Diseases
o
By Product
§
Vaccines
§
MABs
§
Antisense,
RNAi, & Molecular Therapy
§
Recombinant
Proteins
§
Others
·
Immunological
Disorders
·
Cardiovascular
Disorders
·
Hematological
Disorders
·
Others
Biologics Regional Outlook (Revenue, USD
Billion, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
Middle East
and Africa (MEA)
o
South Africa
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For more
market analysis reports, please visit: http://www.grandviewresearch.com/
No comments:
Post a Comment